80. Targeted cancer immunotherapies, Chip Clark, President and CEO, Genocea
Chip has served as Genocea's President and Chief Executive Officer since February 2011 after serving as Chief Business Officer from August 2010 to February 2011. Chip has also served on Genocea's boar...
17 Marras 202129min
79. Leadership in rare diseases, Srini Ramanathan, SVP, R&D Sciences, Horizon Therapeutics
Srini Ramanathan, Ph.D., Senior Vice President, Research and Development Sciences Srini Ramanathan, Ph.D., joined Horizon Therapeutics in 2018. He leads Horizon’s research and development sciences, w...
10 Marras 202127min
78. Translating lab insights for outcomes to cancer patients, Heike Keilhack, CSO,Ribon Therapeutics
Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology and translational medicine with over 15 years of experience in oncology dru...
3 Marras 202129min
77. Battling rare diseases: patients and scientists, Ethan Perlstein, Founder and CEO, Perlara
Dr. Ethan Perlstein is the founder and CEO of Perlara PBC, the first biotech public benefit company established in 2014 that partners with highly motivated and entrepreneurial families and foundations...
27 Loka 202126min
76. Advancing immuno-oncology, Michel Detheux, President and CEO, iTeos Therapeutics
Michel Detheux is the co-founder, President, and CEO of iTeos Therapeutics, and has held the role of CEO since the company’s inception in 2012. He previously served as a director at Ludwig Cancer Rese...
20 Loka 202121min
75. Innovations in cell therapies via microfluidics, Armon Sharei, CEO and Founder, SQZ Biotech
Armon Sharei, PhD, is the Chief Executive Officer and Founder of SQZ Biotechnologies, a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients arou...
13 Loka 202130min
74. Pioneering circular oRNA therapeutics, Thomas Barnes, Chief Executive Officer, Orna Therapeutics
Thomas is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations for over 20 years and has co-founded or helped la...
6 Loka 202124min
73. Patient focused gene editing for heart disease, Andrew Bellinger, CSO/CMO, Verve Therapeutics
Andrew Bellinger is chief scientific officer of Verve Therapeutics. He is a general cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine...
29 Syys 202122min
